KR20230027213A - 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 - Google Patents
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 Download PDFInfo
- Publication number
- KR20230027213A KR20230027213A KR1020237002102A KR20237002102A KR20230027213A KR 20230027213 A KR20230027213 A KR 20230027213A KR 1020237002102 A KR1020237002102 A KR 1020237002102A KR 20237002102 A KR20237002102 A KR 20237002102A KR 20230027213 A KR20230027213 A KR 20230027213A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- trans
- cyclohexyl
- alkyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043612P | 2020-06-24 | 2020-06-24 | |
| US63/043,612 | 2020-06-24 | ||
| PCT/US2021/038625 WO2021262812A1 (en) | 2020-06-24 | 2021-06-23 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230027213A true KR20230027213A (ko) | 2023-02-27 |
Family
ID=79032406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237002102A Pending KR20230027213A (ko) | 2020-06-24 | 2021-06-23 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11739075B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171568B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7778095B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230027213A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115955979B (cg-RX-API-DMAC7.html) |
| AR (1) | AR122725A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3048462T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202216681A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021262812A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| WO2022262782A1 (zh) * | 2021-06-17 | 2022-12-22 | 南京明德新药研发有限公司 | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 |
| US20240408085A1 (en) | 2021-09-01 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| KR20250020448A (ko) | 2022-06-02 | 2025-02-11 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용 |
| TW202530189A (zh) | 2023-09-29 | 2025-08-01 | 日商第一三共股份有限公司 | 3-苯基丙基胺衍生物 |
| CN122497677A (zh) | 2023-10-20 | 2026-07-31 | 奇树医药公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
| AR088082A1 (es) * | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| WO2015179434A1 (en) * | 2014-05-20 | 2015-11-26 | Ohio State Innovation Foundation | Small molecule ras inhibitors |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN110317192A (zh) * | 2018-03-28 | 2019-10-11 | 上海美志医药科技有限公司 | 一类具有降解雄激素受体活性的化合物 |
| BR112021011968A2 (pt) | 2018-12-19 | 2021-09-08 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
| AU2019404022A1 (en) | 2018-12-19 | 2021-07-08 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
-
2021
- 2021-06-23 JP JP2022579835A patent/JP7778095B2/ja active Active
- 2021-06-23 EP EP21830097.8A patent/EP4171568B1/en active Active
- 2021-06-23 AR ARP210101737A patent/AR122725A1/es not_active Application Discontinuation
- 2021-06-23 ES ES21830097T patent/ES3048462T3/es active Active
- 2021-06-23 KR KR1020237002102A patent/KR20230027213A/ko active Pending
- 2021-06-23 CN CN202180044305.0A patent/CN115955979B/zh active Active
- 2021-06-23 US US17/356,305 patent/US11739075B2/en active Active
- 2021-06-23 WO PCT/US2021/038625 patent/WO2021262812A1/en not_active Ceased
- 2021-06-23 TW TW110122924A patent/TW202216681A/zh unknown
-
2023
- 2023-07-07 US US18/219,511 patent/US12227490B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4171568B1 (en) | 2025-08-27 |
| US11739075B2 (en) | 2023-08-29 |
| US20210403453A1 (en) | 2021-12-30 |
| WO2021262812A1 (en) | 2021-12-30 |
| ES3048462T3 (en) | 2025-12-10 |
| EP4171568A1 (en) | 2023-05-03 |
| AR122725A1 (es) | 2022-09-28 |
| JP2023531709A (ja) | 2023-07-25 |
| CN115955979B (zh) | 2025-12-05 |
| US12227490B2 (en) | 2025-02-18 |
| JP7778095B2 (ja) | 2025-12-01 |
| US20230348431A1 (en) | 2023-11-02 |
| EP4171568A4 (en) | 2024-07-24 |
| CN115955979A (zh) | 2023-04-11 |
| TW202216681A (zh) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4171568B1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| US12103920B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| US11560371B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| WO2022272074A1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091356A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091356B (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| US20250100995A1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| KR20240025613A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
| HK40091357A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091357B (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |